At this juncture and more immediate I believe we are looking for a second license agreement with our lead drug Brilacidin this time for the treatment of oral mucositis (OM). Brilacidin for OM is FDA phase3 approved.

Read more on Brilacidin including our first license agreement with Alfasigma pharma for the treatment of IBS on the company website.

IPIX has no sales. Locust Walk has been engaged to help us out in our next licensing effort. Just have to wait and see what happens.

http://www.ipharminc.com/press-release